IPN Ipsen SA

IPSEN: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS--(BUSINESS WIRE)--

Regulatory News:

IPSEN:

Place de cotation : Euronext Paris

Code ISIN : FR 0010259150

LEI : 549300M6SGDPB4Z94P11

 

Date

 

Nombre total

d’actions

composant le capital

social

Nombre total

de droits de vote

30 juin 2019

83 808 761

 

Total brut des droits de vote : 131 956 567

 

 

Total net* des droits de vote : 131 320 221

 

*Total net = nombre total de droits de vote attachés au nombre total d’actions – actions privées de droits de vote

FR
30/07/2019

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

February 27, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

February 27, 2026 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch